[
  {
    "ts": null,
    "headline": "Trump Threatens Pharma Tariffs This Month. Why the Stocks Are Looking Healthy.",
    "summary": "Trump has again threatened the multibillion-dollar pharmaceutical sector with high tariffs unless they move production to the U.S.",
    "url": "https://finnhub.io/api/news?id=448f593dcc2fcaff7ce0f76ae6948953b4e572c7fe3374e6435eac06eeae5e30",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752662100,
      "headline": "Trump Threatens Pharma Tariffs This Month. Why the Stocks Are Looking Healthy.",
      "id": 135964841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Trump has again threatened the multibillion-dollar pharmaceutical sector with high tariffs unless they move production to the U.S.",
      "url": "https://finnhub.io/api/news?id=448f593dcc2fcaff7ce0f76ae6948953b4e572c7fe3374e6435eac06eeae5e30"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson shrugs off tariff impact and forecasts sales boost",
    "summary": "Johnson & Johnson has shrugged off the impact of tariffs as the US-based healthcare group raised its earnings and sales guidance for 2025. J...",
    "url": "https://finnhub.io/api/news?id=682785971e5c5fd91bbbdc36c049d3f2dd070d4a886b35947d140bf1cc92d0a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752661507,
      "headline": "Johnson & Johnson shrugs off tariff impact and forecasts sales boost",
      "id": 135965004,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Johnson & Johnson has shrugged off the impact of tariffs as the US-based healthcare group raised its earnings and sales guidance for 2025. J...",
      "url": "https://finnhub.io/api/news?id=682785971e5c5fd91bbbdc36c049d3f2dd070d4a886b35947d140bf1cc92d0a8"
    }
  },
  {
    "ts": null,
    "headline": "Why Merck Is A Better Dividend Stock Than Gilead Sciences",
    "summary": "Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for our updates on GILD and MRK.",
    "url": "https://finnhub.io/api/news?id=3cadfa7a66dbe4895300ba5134ba960e57d6f80120e8fcac3740403e49c60606",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752678509,
      "headline": "Why Merck Is A Better Dividend Stock Than Gilead Sciences",
      "id": 135970484,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1187806357/image_1187806357.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for our updates on GILD and MRK.",
      "url": "https://finnhub.io/api/news?id=3cadfa7a66dbe4895300ba5134ba960e57d6f80120e8fcac3740403e49c60606"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson, Amgen share gains lead Dow's 229-point jump",
    "summary": "Johnson & Johnson, Amgen share gains lead Dow's 229-point jump",
    "url": "https://finnhub.io/api/news?id=d4782c7b39a8beb3653018a7c1d810e0f711de118ad25008a0c5294e6bc8e4ba",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752678060,
      "headline": "Johnson & Johnson, Amgen share gains lead Dow's 229-point jump",
      "id": 135974786,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson, Amgen share gains lead Dow's 229-point jump",
      "url": "https://finnhub.io/api/news?id=d4782c7b39a8beb3653018a7c1d810e0f711de118ad25008a0c5294e6bc8e4ba"
    }
  },
  {
    "ts": null,
    "headline": "Grignard Reagents Global Market Forecast Report 2025-2030 | Emergence of Green Chemistry and Sustainable Practices, & Rising Demand in Asia-Pacific Driving Multi-Billion Opportunities",
    "summary": "The global Grignard reagents market is projected to grow from USD 5.07 billion in 2025 to USD 6.67 billion by 2030, at a CAGR of 5.6%. Aryl Grignard reagents hold a significant share due to their stability and reactivity, essential for synthesizing pharmaceuticals and agrochemicals. The market, particularly in North America, is driven by high demand from the pharmaceutical, agrochemical, and advanced materials sectors. Top players like Merck and Albemarle dominate the landscape. The growing agri",
    "url": "https://finnhub.io/api/news?id=fc4f994f1cfa2353d17936c241b1aa170ad955bd27eee2fc6664d809be518333",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752675300,
      "headline": "Grignard Reagents Global Market Forecast Report 2025-2030 | Emergence of Green Chemistry and Sustainable Practices, & Rising Demand in Asia-Pacific Driving Multi-Billion Opportunities",
      "id": 135993388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The global Grignard reagents market is projected to grow from USD 5.07 billion in 2025 to USD 6.67 billion by 2030, at a CAGR of 5.6%. Aryl Grignard reagents hold a significant share due to their stability and reactivity, essential for synthesizing pharmaceuticals and agrochemicals. The market, particularly in North America, is driven by high demand from the pharmaceutical, agrochemical, and advanced materials sectors. Top players like Merck and Albemarle dominate the landscape. The growing agri",
      "url": "https://finnhub.io/api/news?id=fc4f994f1cfa2353d17936c241b1aa170ad955bd27eee2fc6664d809be518333"
    }
  },
  {
    "ts": null,
    "headline": "Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?",
    "summary": "RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.",
    "url": "https://finnhub.io/api/news?id=46b07fba8b0fbfa5e58c5463b412b188b5e697c73f39ec2dae66296eeaeca00a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752674280,
      "headline": "Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?",
      "id": 135993389,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.",
      "url": "https://finnhub.io/api/news?id=46b07fba8b0fbfa5e58c5463b412b188b5e697c73f39ec2dae66296eeaeca00a"
    }
  },
  {
    "ts": null,
    "headline": "Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)",
    "summary": "Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best oversold NASDAQ stocks to buy now. On June 20, Mizuho analyst Salim Syed commented on Vaxcyte, Inc. (NASDAQ:PCVX), on which the firm maintained an Outperform rating. Syed’s comment followed reports that Health and Human Services Secretary Kennedy was considering a review of licensed vaccines containing aluminum adjuvants. The […]",
    "url": "https://finnhub.io/api/news?id=8787991a12031f54d8c727f11cd2dcba272759e78914fdee7fc0e912b6deb59c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752673138,
      "headline": "Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)",
      "id": 135967687,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Vaxcyte, Inc. (NASDAQ:PCVX) is one of the best oversold NASDAQ stocks to buy now. On June 20, Mizuho analyst Salim Syed commented on Vaxcyte, Inc. (NASDAQ:PCVX), on which the firm maintained an Outperform rating. Syed’s comment followed reports that Health and Human Services Secretary Kennedy was considering a review of licensed vaccines containing aluminum adjuvants. The […]",
      "url": "https://finnhub.io/api/news?id=8787991a12031f54d8c727f11cd2dcba272759e78914fdee7fc0e912b6deb59c"
    }
  },
  {
    "ts": null,
    "headline": "Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet",
    "summary": "The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
    "url": "https://finnhub.io/api/news?id=3258c70c574989024d2caeaf835930eda15f64e68aea1114ed1e59d0da68f584",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752672604,
      "headline": "Brokers Suggest Investing in Merck (MRK): Read This Before Placing a Bet",
      "id": 135993391,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?",
      "url": "https://finnhub.io/api/news?id=3258c70c574989024d2caeaf835930eda15f64e68aea1114ed1e59d0da68f584"
    }
  },
  {
    "ts": null,
    "headline": "Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy.",
    "summary": "Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy.",
    "url": "https://finnhub.io/api/news?id=97ab44abf5ee1b1e0d567b77c8e08918c45866d82561979061d15f1dab32bc80",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752669900,
      "headline": "Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy.",
      "id": 135975027,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Trump Threatens Pharma Tariffs Soon. Why the Stocks Are Looking Healthy.",
      "url": "https://finnhub.io/api/news?id=97ab44abf5ee1b1e0d567b77c8e08918c45866d82561979061d15f1dab32bc80"
    }
  },
  {
    "ts": null,
    "headline": "Will Increased Expenses Affect Bristol Myers' Performance?",
    "summary": "BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.",
    "url": "https://finnhub.io/api/news?id=26b85ad65875faabc2cf17723e2b11cad625d21da4b7d94680d13a62398a9cc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752669660,
      "headline": "Will Increased Expenses Affect Bristol Myers' Performance?",
      "id": 135993392,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.",
      "url": "https://finnhub.io/api/news?id=26b85ad65875faabc2cf17723e2b11cad625d21da4b7d94680d13a62398a9cc3"
    }
  },
  {
    "ts": null,
    "headline": "How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?",
    "summary": "ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.",
    "url": "https://finnhub.io/api/news?id=794b7a8719fabfd42c7d66b74bfaa85f5cb7149999cdcfea6e06bd67ac23205a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752669540,
      "headline": "How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?",
      "id": 135993161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.",
      "url": "https://finnhub.io/api/news?id=794b7a8719fabfd42c7d66b74bfaa85f5cb7149999cdcfea6e06bd67ac23205a"
    }
  },
  {
    "ts": null,
    "headline": "Ora Appoints Industry Veteran Bill Sharbaugh as Chairman of the Board of Directors",
    "summary": "BOSTON, July 16, 2025--Leading global ophthalmic CRO Ora announces appointment of pharmaceutical industry veteran Bill Sharbaugh as Chairman of Board of Directors.",
    "url": "https://finnhub.io/api/news?id=03cd655922e9e2c81017d2bf01e2d08b0dde6d32fdefe3ad172a50c2fc50189e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752669000,
      "headline": "Ora Appoints Industry Veteran Bill Sharbaugh as Chairman of the Board of Directors",
      "id": 135965221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BOSTON, July 16, 2025--Leading global ophthalmic CRO Ora announces appointment of pharmaceutical industry veteran Bill Sharbaugh as Chairman of Board of Directors.",
      "url": "https://finnhub.io/api/news?id=03cd655922e9e2c81017d2bf01e2d08b0dde6d32fdefe3ad172a50c2fc50189e"
    }
  },
  {
    "ts": null,
    "headline": "This Blue-Chip Stock Is 20% Off Its Highs. Should You Buy the Dip?",
    "summary": "Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.",
    "url": "https://finnhub.io/api/news?id=68b43b8b7273a49533e77fd879cc1ac778337327540f367fe2bfcce1a2c8fdd0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752665402,
      "headline": "This Blue-Chip Stock Is 20% Off Its Highs. Should You Buy the Dip?",
      "id": 135965222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Shares are down in the year to date and 20% off their 52-week high, but analysts see 30% upside ahead for Pfizer.",
      "url": "https://finnhub.io/api/news?id=68b43b8b7273a49533e77fd879cc1ac778337327540f367fe2bfcce1a2c8fdd0"
    }
  },
  {
    "ts": null,
    "headline": "Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment",
    "summary": "Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the successful achievement of a discovery research milestone under its exclusive research collaboration and licence agreement with Merck. In conjunction with the milestone achieveme",
    "url": "https://finnhub.io/api/news?id=cf0b81eb40aeb6aa5c7818a214267f932bc1ba4de023f1c4fa60207ab5f82354",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752663600,
      "headline": "Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment",
      "id": 135965223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the successful achievement of a discovery research milestone under its exclusive research collaboration and licence agreement with Merck. In conjunction with the milestone achieveme",
      "url": "https://finnhub.io/api/news?id=cf0b81eb40aeb6aa5c7818a214267f932bc1ba4de023f1c4fa60207ab5f82354"
    }
  }
]